Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk Clinical Perspectives and Basic Implications

被引:90
|
作者
Aragam, Krishna G.
Natarajan, Pradeep
机构
[1] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA
[2] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA
[3] Harvard Med Sch, Dept Med, Boston, MA 02115 USA
关键词
atherosclerosis; cardiovascular disease; coronary artery disease; genome-wide association study; genotype; CORONARY-HEART-DISEASE; GENOME-WIDE ASSOCIATION; SINGLE NUCLEOTIDE POLYMORPHISMS; GENETIC RISK; FAMILIAL HYPERCHOLESTEROLEMIA; ARTERY-DISEASE; MYOCARDIAL-INFARCTION; PREDICTIVE ACCURACY; GENERAL-POPULATION; INCREMENTAL VALUE;
D O I
10.1161/CIRCRESAHA.120.315928
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An individual's susceptibility to atherosclerotic cardiovascular disease is influenced by numerous clinical and lifestyle factors, motivating the multifaceted approaches currently endorsed for primary and secondary cardiovascular disease prevention. With growing knowledge of the genetic basis of atherosclerotic cardiovascular disease-in particular, coronary artery disease-and its contribution to disease pathogenesis, there is increased interest in understanding the potential clinical utility of a genetic predictor that might further refine the assessment and management of atherosclerotic cardiovascular disease risk. Rapid scientific and technological advances have enabled widespread genotyping efforts and dynamic research in the field of coronary artery disease genetic risk prediction. In this review, we describe how genomic analyses of coronary artery disease have been leveraged to create polygenic risk scores. We then discuss evaluations of the clinical utility of these scores, pertinent mechanistic insights gleaned, and practical considerations relevant to the implementation of polygenic risk scores in the health care setting.
引用
收藏
页码:1159 / 1177
页数:19
相关论文
共 50 条
  • [1] Clinical Implications of Integrating Polygenic Risk Into Established Cardiovascular Disease Risk Scores
    Riveros-Mckay, Fernando
    Selzam, Saskia
    Seth, Priyanka
    Moore, Rachel
    Tarran, William A.
    O'Sullivan, Jack W.
    Ashley, Euan A.
    McVean, Gilean
    Plagnol, Vincent
    Donnelly, Peter
    Weale, Michael E.
    [J]. CIRCULATION, 2021, 144
  • [2] Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation
    Levin, Michael G.
    Rader, Daniel J.
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 37 (03)
  • [3] Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease
    Smith, Johanna L.
    Schaid, Daniel J.
    Kullo, Iftikhar J.
    [J]. CURRENT ATHEROSCLEROSIS REPORTS, 2023, 25 (06) : 323 - 330
  • [4] Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease
    Johanna L. Smith
    Daniel J. Schaid
    Iftikhar J. Kullo
    [J]. Current Atherosclerosis Reports, 2023, 25 : 323 - 330
  • [5] Possible clinical usefulness of polygenic risk scores among patients with established atherosclerotic cardiovascular disease
    Tamura, Kouichi
    Kumagai, Tomohiro
    Kobayashi, Kazuo
    [J]. ATHEROSCLEROSIS, 2022, 350 : 100 - 101
  • [6] Polygenic risk scores for cardiovascular disease prediction in the clinical practice: Are we there?
    Paquette, Martine
    Baass, Alexis
    [J]. ATHEROSCLEROSIS, 2022, 340 : 46 - 47
  • [7] Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization
    Anna C. F. Lewis
    Emma F. Perez
    Anya E. R. Prince
    Hana R. Flaxman
    Lizbeth Gomez
    Deanna G. Brockman
    Paulette D. Chandler
    Benjamin J. Kerman
    Matthew S. Lebo
    Jordan W. Smoller
    Scott T. Weiss
    Carrie L. Blout Zawatksy
    James B. Meigs
    Robert C. Green
    Jason L. Vassy
    Elizabeth W. Karlson
    [J]. Genome Medicine, 14
  • [8] Patient and provider perspectives on polygenic risk scores: implications for clinical reporting and utilization
    Lewis, Anna C. F.
    Perez, Emma F.
    Prince, Anya E. R.
    Flaxman, Hana R.
    Gomez, Lizbeth
    Brockman, Deanna G.
    Chandler, Paulette D.
    Kerman, Benjamin J.
    Lebo, Matthew S.
    Smoller, Jordan W.
    Weiss, Scott T.
    Zawatksy, Carrie L. Blout
    Meigs, James B.
    Green, Robert C.
    Vassy, Jason L.
    Karlson, Elizabeth W.
    [J]. GENOME MEDICINE, 2022, 14 (01)
  • [9] Ancestry-specific polygenic risk scores are risk enhancers for clinical cardiovascular disease assessments
    George B. Busby
    Scott Kulm
    Alessandro Bolli
    Jen Kintzle
    Paolo Di Domenico
    Giordano Bottà
    [J]. Nature Communications, 14
  • [10] Ancestry-specific polygenic risk scores are risk enhancers for clinical cardiovascular disease assessments
    Busby, George B.
    Kulm, Scott
    Bolli, Alessandro
    Kintzle, Jen
    Domenico, Paolo Di
    Botta, Giordano
    [J]. NATURE COMMUNICATIONS, 2023, 14 (01)